GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBMFF) » Definitions » Quality Rank

Sino Biopharmaceutical (Sino Biopharmaceutical) Quality Rank


View and export this data going back to 2010. Start your Free Trial

What is Sino Biopharmaceutical Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Sino Biopharmaceutical Quality Rank Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical (Sino Biopharmaceutical) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBMFF) » Definitions » Quality Rank
Comparable Companies
HKSE:02269 HKSE:01801 HKSE:09926 HKSE:06990 HKSE:01877 HKSE:09995 HKSE:01548 HKSE:06826 HKSE:01530 HKSE:06660 OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
SBHMY:USA 01177:Hong Kong SMZ1:Germany
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Website
https://www.sinobiopharm.com
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.